{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:01:00Z","timestamp":1788843660946,"version":"build-2803163510"},"reference-count":52,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":265,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.csbj.2023.09.028","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:19:31Z","timestamp":1695730771000},"page":"4717-4728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thyroxine metabolite-derived 3-iodothyronamine (T1AM) and synthetic analogs as efficient suppressors of transthyretin amyloidosis"],"prefix":"10.34133","volume":"21","author":[{"given":"Bokyung","family":"Kim","sequence":"first","affiliation":[{"name":"Department of New Biology, Daegu Gyeongbuk Institute of Science & Technology (DGIST), Daegu 42988, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ho","family":"Ko","sequence":"additional","affiliation":[{"name":"Center for Self-Assembly and Complexity, Institute for Basic Science, Pohang 37673, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbeom","family":"Si","sequence":"additional","affiliation":[{"name":"Department of New Biology, Daegu Gyeongbuk Institute of Science & Technology (DGIST), Daegu 42988, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongbum","family":"Na","sequence":"additional","affiliation":[{"name":"Department of New Biology, Daegu Gyeongbuk Institute of Science & Technology (DGIST), Daegu 42988, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ortore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, 56100 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Chiellini","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pisa, 56100 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of New Biology, Daegu Gyeongbuk Institute of Science & Technology (DGIST), Daegu 42988, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1210\/er.2018-00182","article-title":"3-Iodothyronamine-A thyroid hormone metabolite with distinct target profiles and mode of action","volume":"40","author":"K\u00f6hrle J.","year":"2019","unstructured":"K\u00f6hrle J. and Biebermann H.: 3-Iodothyronamine-A thyroid hormone metabolite with distinct target profiles and mode of action. Endocr Rev 2019; 40: 620.","journal-title":"Endocr Rev"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acel.13260","article-title":"Thyroid hormones in diabetes, cancer, and aging","volume":"19","author":"Gauthier B.R.","year":"2020","unstructured":"Gauthier B.R., Sola\u2010Garc\u00eda A., C\u00e1liz\u2010Molina M.\u00c1., Lorenzo P.I., Cobo\u2010Vuilleumier N., Capilla\u2010Gonz\u00e1lez V. et al: Thyroid hormones in diabetes, cancer, and aging. Aging Cell 2020; 19: 1.","journal-title":"Aging Cell"},{"key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm1051","article-title":"3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone","volume":"10","author":"Scanlan T.S.","year":"2004","unstructured":"Scanlan T.S., Suchland K.L., Hart M.E., Chiellini G., Huang Y., Kruzich P.J. et al: 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 2004; 10: 638.","journal-title":"Nat Med"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000430839","article-title":"Evolutionary conservation of 3-iodothyronamine as an agonist at the trace amine-associated receptor 1","volume":"4","author":"C\u00f6ster M.","year":"2015","unstructured":"C\u00f6ster M., Biebermann H., Sch\u00f6neberg T. and St\u00e4ubert C.: Evolutionary conservation of 3-iodothyronamine as an agonist at the trace amine-associated receptor 1. Eur Thyroid J 2015; 4: 9.","journal-title":"Eur Thyroid J"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00905","article-title":"New insights into the potential roles of 3-iodothyronamine (T1AM) and newly developed thyronamine-like TAAR1 agonists in neuroprotection","volume":"8","author":"Bellusci L.","year":"2017","unstructured":"Bellusci L., Laurino A., Sabatini M., Sestito S., Lenzi P., Raimondi L. et al: New insights into the potential roles of 3-iodothyronamine (T1AM) and newly developed thyronamine-like TAAR1 agonists in neuroprotection. Front Pharm 2017; 8: 1.","journal-title":"Front Pharm"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/molecules26061616","article-title":"Delivery of thyronamines (Tams) to the brain: a preliminary study","volume":"26","author":"di Leo N.","year":"2021","unstructured":"di Leo N., Moscato S., Borso\u2019 M., Sestito S., Polini B., Bandini L. et al: Delivery of thyronamines (Tams) to the brain: a preliminary study. Molecules 2021; 26: 1616.","journal-title":"Molecules"},{"key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules25051054","article-title":"Endogenous 3-iodothyronamine (T1Am) and synthetic thyronamine-like analog SG-2 act as novel pleiotropic neuroprotective agents through the modulation of SIRT6","volume":"25","author":"Bellusci L.","year":"2020","unstructured":"Bellusci L., Runfola M., Carnicelli V., Sestito S., Fulceri F., Santucci F. et al: Endogenous 3-iodothyronamine (T1Am) and synthetic thyronamine-like analog SG-2 act as novel pleiotropic neuroprotective agents through the modulation of SIRT6. Molecules 2020; 25: 1.","journal-title":"Molecules"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174606","article-title":"The 3-iodothyronamine (T1AM) and the 3-iodothyroacetic acid (TA1) indicate a novel connection with the histamine system for neuroprotection","volume":"912","author":"Laurino A.","year":"2021","unstructured":"Laurino A., Gencarelli M. and Raimondi L.: The 3-iodothyronamine (T1AM) and the 3-iodothyroacetic acid (TA1) indicate a novel connection with the histamine system for neuroprotection. Eur J Pharmacol 2021; 912: 174606.","journal-title":"Eur J Pharmacol"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1111\/bph.12697","article-title":"Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism","volume":"171","author":"Musilli C.","year":"2014","unstructured":"Musilli C., De Siena G., Manni M.E., Logli A., Landucci E., Zucchi R. et al: Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism. Br J Pharmacol 2014; 171: 3476.","journal-title":"Br J Pharmacol"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1021\/acs.jmedchem.5b00526","article-title":"Design, synthesis, and evaluation of thyronamine analogues as novel potent mouse trace amine associated receptor 1 (m TAAR1) agonists","volume":"58","author":"Chiellini G.","year":"2015","unstructured":"Chiellini G., Nesi G., Digiacomo M., Malvasi R., Espinoza S., Sabatini M. et al: Design, synthesis, and evaluation of thyronamine analogues as novel potent mouse trace amine associated receptor 1 (m TAAR1) agonists. J Med Chem 2015; 58: 5096.","journal-title":"J Med Chem"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062005","article-title":"3-iodothyronamine and derivatives: new allies against metabolic syndrome?","volume":"21","author":"Rutigliano G.","year":"2020","unstructured":"Rutigliano G., Bandini L., Sestito S. and Chiellini G.: 3-iodothyronamine and derivatives: new allies against metabolic syndrome?. Int J Mol Sci 2020; 21.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0272-2712(18)30427-X","article-title":"Thyroid hormone transport proteins","volume":"13","author":"Bartalena L.","year":"1993","unstructured":"Bartalena L. and Robbins J.: Thyroid hormone transport proteins. Clin Lab Med 1993; 13: 583.","journal-title":"Clin Lab Med"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53792-3"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1107\/S0907444996003046","article-title":"Structures of human transthyretin complexed with thyroxine at 2.0 \u00c5 resolution and 3\u2032,5\u2032-dinitro- N -acetyl- L -thyronine at 2.2 \u00c5 resolution","volume":"52","author":"Wojtczak A.","year":"1996","unstructured":"Wojtczak A., Cody V., Luft J.R. and Pangborn W.: Structures of human transthyretin complexed with thyroxine at 2.0 \u00c5 resolution and 3\u2032,5\u2032-dinitro- N -acetyl- L -thyronine at 2.2 \u00c5 resolution. Acta Crystallogr D Biol Crystallogr 1996; 52: 758.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","article-title":"Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy","volume":"75","author":"Costa P.P.","year":"1978","unstructured":"Costa P.P., Figueira A.S. and Bravo F.R.: Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 1978; 75: 4499.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark P.","year":"1990","unstructured":"Westermark P., Sletten K., Johansson B. and Cornwell G.G.: Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87: 2843.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.12.060"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan M.","year":"2016","unstructured":"Grogan M., Scott C.G., Kyle R.A., Zeldenrust S.R., Gertz M.A., Lin G. et al: Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016; 68: 1014.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_5_20_2","article-title":"Transthyretin misfolding, a fatal structural pathogenesis mechanism","volume":"22","author":"Si J.B.","year":"2021","unstructured":"Si J.B., Kim B. and Kim J.H.: Transthyretin misfolding, a fatal structural pathogenesis mechanism. Int J Mol Sci 2021; 22.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy G.J.","year":"1996","unstructured":"Miroy G.J., Lai Z., Lashuel H.A., Peterson S.A., Strang C. and Kelly J.W.: Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 1996; 93: 15051.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121005109"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/13506129.2016.1236332","article-title":"Tafamidis in hereditary ATTR amyloidosis \u2013 our experience on monitoring the ocular manifestations","volume":"23","author":"Casal I.","year":"2016","unstructured":"Casal I., Monteiro S. and Beir\u00e3o J.M.: Tafamidis in hereditary ATTR amyloidosis \u2013 our experience on monitoring the ocular manifestations. Amyloid 2016; 23: 262.","journal-title":"Amyloid"},{"key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.033","article-title":"Failure of tafamidis to halt progression of Ala36Pro TTR oculomeningovascular amyloidosis","volume":"27","author":"Salvi F.","year":"2018","unstructured":"Salvi F., Volpe R., Pastorelli F., Bianchi A., Vella A., Rapezzi C. et al: Failure of tafamidis to halt progression of Ala36Pro TTR oculomeningovascular amyloidosis. J Stroke Cereb Dis 2018; 27: e212.","journal-title":"J Stroke Cereb Dis"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201608516"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(02)00471-0"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.8b00642"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab180"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi952501g"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi500739q"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.235"},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/cmdc.201700051","article-title":"Identification of transthyretin fibril formation inhibitors using structure-based virtual screening","volume":"12","author":"Ortore G.","year":"2017","unstructured":"Ortore G. and Martinelli A.: Identification of transthyretin fibril formation inhibitors using structure-based virtual screening. ChemMedChem 2017; 12: 1327.","journal-title":"ChemMedChem"},{"key":"e_1_3_5_34_2","unstructured":"D.A. Case R.M. Betz D.S. Cerutti T.E. Cheatham III T.A. Darden R.E. Duke T.J. Giese HG A.W. Goetz N. Homeyer S. Izadi P. Janowski J. Kaus A. Kovalenko T.S. Lee S. LeGrand P. Li C. Lin T. Luchko R. Luo B. Madej D. Mermelstein K.M. Merz G. Monard H. Nguyen H.T. Nguyen I. Omelyan A. Onufriev D.R. Roe A. Roitberg C. Sagui C.L. Simmerling W.M. Botello-Smith JS R.C. Walker J. Wang R.M. Wolf X. Wu LX and P.A.K.. AMBER 2016 University of California San Francisco 2016."},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/ct400341p"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20084"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.24467"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/ct300418h"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00151a036"},{"key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00220559","article-title":"Transthyretin Pro 55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement","volume":"89","author":"Jacobson D.R.","year":"1992","unstructured":"Jacobson D.R., McFarlin D.E., Kane I. and Buxbaum J.N.: Transthyretin Pro 55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet 1992; 89: 353.","journal-title":"Hum Genet"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-4684-5958-6_2","article-title":"Genetic aspects of amyloidosis","volume":"20","author":"Jacobson D.R.","year":"1991","unstructured":"Jacobson D.R. and Buxbaum J.N.: Genetic aspects of amyloidosis. Adv Hum Genet 1991; 20: 69.","journal-title":"Adv Hum Genet"},{"key":"e_1_3_5_42_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113847","article-title":"Targeting transthyretin in Alzheimer\u2019s disease: drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\u2019s disease","volume":"226","author":"Cotrina E.Y.","year":"2021","unstructured":"Cotrina E.Y., Santos L.M., Rivas J., Blasi D., Leite J.P., Liz M.A. et al: Targeting transthyretin in Alzheimer\u2019s disease: drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\u2019s disease. Eur J Med Chem 2021; 226: 113847.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_5_43_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117370","article-title":"Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis","volume":"90","author":"Mizuguchi M.","year":"2023","unstructured":"Mizuguchi M., Yokoyama T., Okada T., Nakagawa Y., Fujii K., Nabeshima Y. et al: Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis. Bioorg Med Chem 2023; 90.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1107\/S2052252514021113"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijms.2004.05.013"},{"key":"e_1_3_5_46_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21228672","article-title":"Transthyretin stabilization: an emerging strategy for the treatment of alzheimer\u2019s disease?","volume":"21","author":"Saponaro F.","year":"2020","unstructured":"Saponaro F., Kim J.H. and Chiellini G.: Transthyretin stabilization: an emerging strategy for the treatment of alzheimer\u2019s disease?. Int J Mol Sci 2020; 21: 1.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_5_47_2","article-title":"Diphenyl-methane based thyromimetic inhibitors for transthyretin amyloidosis","volume":"22","author":"Kim B.","year":"2021","unstructured":"Kim B., Ko Y.H., Runfola M., Rapposelli S., Ortore G., Chiellini G. et al: Diphenyl-methane based thyromimetic inhibitors for transthyretin amyloidosis. Int J Mol Sci 2021; 22.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_5_48_2","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121330","article-title":"Identification of a thyroid hormone derivative as a pleiotropic agent for the treatment of Alzheimer\u2019s disease","volume":"14","author":"Runfola M.","year":"2021","unstructured":"Runfola M., Perni M., Yang X., Marchese M., Bacci A., Mero S. et al: Identification of a thyroid hormone derivative as a pleiotropic agent for the treatment of Alzheimer\u2019s disease. Pharmaceuticals 2021; 14.","journal-title":"Pharmaceuticals"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.659912"},{"key":"e_1_3_5_50_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ncpendmet0590","article-title":"Potential therapeutic applications of thyroid hormone analogs","volume":"3","author":"Brenta G.","year":"2007","unstructured":"Brenta G., Danzi S. and Klein I.: Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 2007; 3: 632.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"e_1_3_5_51_2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/thy.2020.0071","article-title":"Thyroid hormone analogues: an update","volume":"30","author":"Zucchi R.","year":"2020","unstructured":"Zucchi R.: Thyroid hormone analogues: an update. Thyroid 2020; 30: 1099.","journal-title":"Thyroid"},{"key":"e_1_3_5_52_2","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1074\/jbc.M111.275552","article-title":"ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation","volume":"287","author":"Roy G.","year":"2012","unstructured":"Roy G., Placzek E. and Scanlan T.S.: ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation. J Biol Chem 2012; 287: 1790.","journal-title":"J Biol Chem"},{"key":"e_1_3_5_53_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mce.2017.02.037","article-title":"Directional thyroid hormone distribution via the blood stream to target sites","volume":"458","author":"Janssen S.T.","year":"2017","unstructured":"Janssen S.T. and Janssen O.E.: Directional thyroid hormone distribution via the blood stream to target sites. Mol Cell Endocrinol 2017; 458: 16.","journal-title":"Mol Cell Endocrinol"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037023003409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037023003409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2023.09.028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T21:13:31Z","timestamp":1778015611000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2023.09.028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":52,"alternative-id":["10.1016\/j.csbj.2023.09.028"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2023.09.028","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroxine metabolite-derived 3-iodothyronamine (T1AM) and synthetic analogs as efficient suppressors of transthyretin amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2023.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}